2023 Senate Bill 483

Health: pharmaceuticals; prescription drug cost and affordability review act; create.

A bill to provide for a cost and affordability review of certain prescription drug products; to create the prescription drug pricing board and prescription drug affordability stakeholder council and to prescribe their powers and duties; to provide for the powers and duties of certain state governmental officers and entities; to establish upper payment limits for certain prescription drug products and provide remedies; and to provide for the promulgation of rules.

Official record

Introduced in the Senate

Sept. 12, 2023

Introduced by Sen. Darrin Camilleri (D-4) and 17 co-sponsors

Co-sponsored by Sens. Kristen McDonald Rivet (D-35), Veronica Klinefelt (D-11), Jeremy Moss (D-7), John Cherry (D-27), Rosemary Bayer (D-13), Dayna Polehanki (D-5), Mallory McMorrow (D-8), Paul Wojno (D-10), Sylvia Santana (D-2), Mary Cavanagh (D-6), Sam Singh (D-28), Stephanie Chang (D-3), Erika Geiss (D-1), Winnie Brinks (D-29), Sue Shink (D-14), Jeff Irwin (D-15) and Sarah Anthony (D-21)

Referred to the Committee on Finance, Insurance, and Consumer Protection

Sept. 27, 2023

Reported with substitute S-1

Sept. 28, 2023

Referred to the Committee of the Whole

Oct. 3, 2023

Reported with substitute S-1

Substitute S-1 concurred in by voice vote

Oct. 4, 2023

Amendment offered by Sen. Jim Runestad (R-23)

1. Amend page 4, line 20, after “activities.” by inserting “The governor shall not appoint an individual to the board if the individual is a lobbyist who is registered in this state. An individual who is appointed to the board shall not register as a lobbyist in this state for a period of 5 years after the individual’s term on the board expires.”.

The amendment passed 37 to 0 (details)

Amendment offered by Sen. Jim Runestad (R-23)

1. Amend page 4, line 20, after “activities.” by inserting “The governor shall not appoint an individual to the board if the individual has made a personal political contribution to the governor.”.

The amendment failed 17 to 20 (details)

Amendment offered by Sen. Michael Webber (R-9)

1. Amend page 4, line 13, after “medicine.” by inserting “At least 1 member of the board must be an individual who advocates for patients.”.

The amendment failed 17 to 20 (details)

Amendment offered by Sen. Aric Nesbitt (R-20)

1. Amend page 15, following line 18, by inserting:

“Sec. 24. This act does not apply beginning 3 years after the effective date of this act.”.

The amendment failed 17 to 20 (details)

Amendment offered by Sen. Lana Theis (R-22)

1. Amend page 12, following line 7, by inserting:

“(j) The cost of manufacturing the prescription drug product.” and relettering the remaining subdivision.

The amendment failed 17 to 20 (details)

Amendment offered by Sen. Lana Theis (R-22)

1. Amend page 2, line 11, after “the” by inserting “medical care component of the”.

2. Amend page 2, line 12, after “Index” by striking out “for all urban consumers as defined and” and inserting “as”.

The amendment failed by voice vote

Passed in the Senate 20 to 17 (details)

Received in the House

Oct. 4, 2023

Referred to the Committee on Insurance and Financial Services